Shares of EXACT Sciences Corporation EXAS are up sharply Friday morning following the company’s announcement that its stool DNA test to detect colorectal cancer has been approved for coverage by the Centers for Medicare and Medicaid Services.
The company reports that, “the approval makes it the only FDA stool test covered by Medicare.”
Shares of EXACT closed Thursday at $18.12 and were recently trading at $24.44, up 34 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in